Industry Focus Transcripts

Self-driving car technology is chugging along. Find out where we are today, and when we might actually be able to buy an autonomous car.

Declining sales increase the stakes for Gilead's most-promising R&D projects.

Carl Icahn's reportedly focusing his brand of investor activism on Bristol-Myers Squibb, but it's anyone's guess if he'll be able to convince the company to sell. Also, Celgene delivers a phase 3 win with blockbuster implications.

Celgene's fallen out of favor with investors, but drugs currently in development might make buying its shares smart.

Transport Topics reporter Eugene Mulero shares what he’s seen at Project Neon and Capitol Hill lately, and what it all means for the future of U.S. infrastructure.

Here's what investors need to know about three big news items.

After struggling for years, some old-fashioned retailers are beginning to see dividends from their investments in e-commerce and other initiatives.

The two companies share a few behind-the-scenes secrets that help make their products and services so appealing to consumers.

After months in limbo, AT&T finally got the green light to acquire Time Warner, and the ripple effects are being felt across the market already.

On the surface, White Mountains Insurance’s business model may look a lot like the Oracle of Omaha’s playbook.

Shareholders breathed a sigh of relief as the Trans Mountain pipeline saga reached a strange conclusion.

The most important things investors need to know about one of the most reliable dividend payers on the market and the biggest pharma in the world, Johnson & Johnson.

All four of the nation’s biggest banks have now reported first quarter earnings. Find out the most important investor takeaways from this year’s Q1 earnings reports.

After 26 down months in a row, Macau's recovery is finally showing legs. Here's what investors should know about the latest developments in the gambling mecca.

The warehouse club industry might not be struggling as much as the traditional grocers, but that doesn’t make this recent IPO an automatic buy.

A new spin on an old drug could dent demand for Epidiolex, a marijuana-based epilepsy drug. Plus, here's how important Medicare and Medicaid are to UnitedHealth Group's profits.

The company behind your smartphone’s glass looks like a pretty compelling long-term investment, but it’s not completely without risk.

Goldman Sachs and Morgan Stanley both had excellent growth in the second quarter.

Investors now have a chance to buy into the "Apple of China." Here’s what you should know before diving in.

The “big four” U.S. banks have all reported second-quarter earnings; here’s a rundown of the results.